A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

This is a phase I, randomised, open-label, single-dose, single-centre, parallel group study investigating the relative bioavailability of two dosage forms of tozorakimab (test dosage form and reference dosage form). The study will comprise of: 1. A screening period of 28 days 2. A Treatment period of 1 day 3. Ambulatory visits on scheduled days c. A final follow-up visit on Day 113 (Week 16)